• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

    9.600 -0.110 (-1.13%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Amneal Pharmaceuticals, Inc. - Class A Common Stock

    < Previous 1 2 Next >
    Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
    Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment 
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
    Expands Amneal’s Affordable Medicines portfolio and broadens patient access 
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Reports Second Quarter 2025 Financial Results
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal to Report Second Quarter 2025 Results on August 5, 2025
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal to Participate at Upcoming Investor Conferences in June
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Reports First Quarter 2025 Financial Results
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Report First Quarter 2025 Results on May 2, 2025
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Participate at Upcoming Investor Conference
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Participate at Upcoming Investor Conferences
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Reports Third Quarter 2024 Financial Results
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Report Third Quarter 2024 Results on November 8, 2024
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.